Latest News

These data, resulting from the INTEGUMENT-OLE trial, highlight the efficacy and safety of roflumilast cream (ZORYVE) 0.05% in children aged 2 - 5 years.

The approval comes after the FDA requested GSK submit an sNDA for leucovorin for the treatment of CFD-FOLR1.

This March episode highlights one SOCS member’s journey in dermatology, covering clinical and research passions as well as lessons learned along the way.

February 2026 saw new data and expert interviews from AAAAI 2026.

The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat in hypertension, but the selective aldosterone synthase inhibitor fell short in a phase 2 obstructive sleep apnea trial.

Phase 3 RAINIER exhibits positive results for povetacicept in adults with IgA Nephropathy in a 36 week interim analysis.

Bimekizumab was assessed using the International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in the BE HEARD I and II studies.

New data suggest those who exhibit minimal early response to ruxolitinib cream may still achieve repigmentation with prolonged use extending to 2 years.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2026.

This Q&A with Neal Bhatia, MD, features a discussion conducted regarding GLP-1 use in patients with psoriasis and obesity or overweight.

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

Twice-daily delgocitinib cream 20 mg/g in those with moderate to severe chronic hand eczema led to significant HRQoL improvements.

Hosts are joined by Su Wang, MD, MPH, to discuss the evolving management of hepatitis B and how to move care beyond silos with expanded treatment and provider empowerment.

The nephrology field continued to see advances in February 2026, with 5 headlines clincians may have missed.

Barzolvolimab therapy resulted in significant improvement of cold urticaria (ColdU) following 20 weeks of treatment.

Pooled REMIX-1/-2 data show remibrutinib reduced CSU activity within 12 hours, with greater UAS improvements vs placebo through day 7.

In this February review of the most significant developments in dermatology, the month’s most notable coverage of disease states such as psoriasis and atopic dermatitis is highlighted.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Lyskjaer walks clinicians through 10-year data from a nationwide cohort study comparing ablation and surgery for renal cancer.

In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management.